Copyright Reports & Markets. All rights reserved.

Global Erdafitinib Tablets Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Erdafitinib Tablets Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 4mg
    • 1.3.3 3mg
  • 1.4 Market Analysis by Packaging
    • 1.4.1 Overview: Global Erdafitinib Tablets Consumption Value by Packaging: 2021 Versus 2025 Versus 2032
    • 1.4.2 Bottle
    • 1.4.3 Box
  • 1.5 Market Analysis by Production Technology
    • 1.5.1 Overview: Global Erdafitinib Tablets Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
    • 1.5.2 Innovator
    • 1.5.3 Generic
  • 1.6 Market Analysis by Sales Channel
    • 1.6.1 Overview: Global Erdafitinib Tablets Consumption Value by Sales Channel: 2021 Versus 2025 Versus 2032
    • 1.6.2 Hospital
    • 1.6.3 Retail
    • 1.6.4 Online
  • 1.7 Market Analysis by Application
    • 1.7.1 Overview: Global Erdafitinib Tablets Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.7.2 Locally Advanced or Metastatic Urothelial Carcinoma with FGFR Abnormalities
    • 1.7.3 Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Mutation
    • 1.7.4 Other Solid Tumors with FGFR Genetic Aberrations
  • 1.8 Global Erdafitinib Tablets Market Size & Forecast
    • 1.8.1 Global Erdafitinib Tablets Consumption Value (2021 & 2025 & 2032)
    • 1.8.2 Global Erdafitinib Tablets Sales Quantity (2021-2032)
    • 1.8.3 Global Erdafitinib Tablets Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Janssen Pharmaceuticals
    • 2.1.1 Janssen Pharmaceuticals Details
    • 2.1.2 Janssen Pharmaceuticals Major Business
    • 2.1.3 Janssen Pharmaceuticals Erdafitinib Tablets Product and Services
    • 2.1.4 Janssen Pharmaceuticals Erdafitinib Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Janssen Pharmaceuticals Recent Developments/Updates

3 Competitive Environment: Erdafitinib Tablets by Manufacturer

  • 3.1 Global Erdafitinib Tablets Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Erdafitinib Tablets Revenue by Manufacturer (2021-2026)
  • 3.3 Global Erdafitinib Tablets Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Erdafitinib Tablets by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Erdafitinib Tablets Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Erdafitinib Tablets Manufacturer Market Share in 2025
  • 3.5 Erdafitinib Tablets Market: Overall Company Footprint Analysis
    • 3.5.1 Erdafitinib Tablets Market: Region Footprint
    • 3.5.2 Erdafitinib Tablets Market: Company Product Type Footprint
    • 3.5.3 Erdafitinib Tablets Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Erdafitinib Tablets Market Size by Region
    • 4.1.1 Global Erdafitinib Tablets Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Erdafitinib Tablets Consumption Value by Region (2021-2032)
    • 4.1.3 Global Erdafitinib Tablets Average Price by Region (2021-2032)
  • 4.2 North America Erdafitinib Tablets Consumption Value (2021-2032)
  • 4.3 Europe Erdafitinib Tablets Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Erdafitinib Tablets Consumption Value (2021-2032)
  • 4.5 South America Erdafitinib Tablets Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Erdafitinib Tablets Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Erdafitinib Tablets Sales Quantity by Type (2021-2032)
  • 5.2 Global Erdafitinib Tablets Consumption Value by Type (2021-2032)
  • 5.3 Global Erdafitinib Tablets Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Erdafitinib Tablets Sales Quantity by Application (2021-2032)
  • 6.2 Global Erdafitinib Tablets Consumption Value by Application (2021-2032)
  • 6.3 Global Erdafitinib Tablets Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Erdafitinib Tablets Sales Quantity by Type (2021-2032)
  • 7.2 North America Erdafitinib Tablets Sales Quantity by Application (2021-2032)
  • 7.3 North America Erdafitinib Tablets Market Size by Country
    • 7.3.1 North America Erdafitinib Tablets Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Erdafitinib Tablets Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Erdafitinib Tablets Sales Quantity by Type (2021-2032)
  • 8.2 Europe Erdafitinib Tablets Sales Quantity by Application (2021-2032)
  • 8.3 Europe Erdafitinib Tablets Market Size by Country
    • 8.3.1 Europe Erdafitinib Tablets Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Erdafitinib Tablets Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Erdafitinib Tablets Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Erdafitinib Tablets Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Erdafitinib Tablets Market Size by Region
    • 9.3.1 Asia-Pacific Erdafitinib Tablets Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Erdafitinib Tablets Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Erdafitinib Tablets Sales Quantity by Type (2021-2032)
  • 10.2 South America Erdafitinib Tablets Sales Quantity by Application (2021-2032)
  • 10.3 South America Erdafitinib Tablets Market Size by Country
    • 10.3.1 South America Erdafitinib Tablets Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Erdafitinib Tablets Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Erdafitinib Tablets Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Erdafitinib Tablets Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Erdafitinib Tablets Market Size by Country
    • 11.3.1 Middle East & Africa Erdafitinib Tablets Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Erdafitinib Tablets Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Erdafitinib Tablets Market Drivers
  • 12.2 Erdafitinib Tablets Market Restraints
  • 12.3 Erdafitinib Tablets Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Erdafitinib Tablets and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Erdafitinib Tablets
  • 13.3 Erdafitinib Tablets Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Erdafitinib Tablets Typical Distributors
  • 14.3 Erdafitinib Tablets Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Erdafitinib Tablets market size was valued at US$ 219 million in 2025 and is forecast to a readjusted size of US$ 523 million by 2032 with a CAGR of 9.2% during review period.
    Erdafitinib is an oral, highly selective small‑molecule pan‑FGFR inhibitor that mainly targets fibroblast growth factor receptors FGFR1–4. It inhibits the activity of receptor tyrosine kinases and blocks downstream signal transduction, thereby suppressing tumor cell proliferation, differentiation and angiogenesis. As the world’s first approved FGFR‑targeted drug for solid tumors, this agent is mainly indicated for advanced malignant tumors with FGFR genetic abnormalities, particularly for locally advanced or metastatic urothelial carcinoma after failure of platinum‑based chemotherapy. It has important clinical value in the precision therapy of solid tumors such as bladder cancer and cholangiocarcinoma, providing a novel targeted therapeutic option for patients with FGFR‑mutant tumors.n 2025, global Erdafitinib production reached approximately 42,000 units.
    As the world’s first approved pan-FGFR inhibitor, Erdafitinib occupies a core position in the precision treatment of FGFR-mutant solid tumors. Its market pattern is characterized by dominance of the innovator drug, impact from generic drugs, and growth driven by medical insurance coverage and indication expansion. As a product of Johnson & Johnson, the drug has established a first-mover advantage owing to its significant efficacy in urothelial carcinoma, while indications are rapidly expanding to more FGFR-mutant cancers such as cholangiocarcinoma and lung cancer.
    The domestic market was approved in early 2025; it has not yet been included in medical insurance, resulting in high prices and limited patient accessibility. Overseas generic versions (from Laos, Bangladesh) divert part of the demand at lower prices, intensifying market competition. Globally, Erdafitinib faces competition from other FGFR inhibitors including pemigatinib and infigratinib. Market competition is gradually shifting from single indications to multi-cancer applications and combination therapies.
    In the future, with the advancement of medical insurance coverage, full launch of generic drugs, expanded indications, and clinical breakthroughs in combination with immunotherapy or anti-angiogenic therapy, the market for Erdafitinib will continue to expand. Meanwhile, the pricing system will become more rational and patient accessibility will be significantly improved.
    This report is a detailed and comprehensive analysis for global Erdafitinib Tablets market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Erdafitinib Tablets market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Erdafitinib Tablets market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Erdafitinib Tablets market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Erdafitinib Tablets market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Erdafitinib Tablets
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Erdafitinib Tablets market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Janssen Pharmaceuticals, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Erdafitinib Tablets market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    4mg
    3mg
    Market segment by Packaging
    Bottle
    Box
    Market segment by Production Technology
    Innovator
    Generic
    Market segment by Sales Channel
    Hospital
    Retail
    Online
    Market segment by Application
    Locally Advanced or Metastatic Urothelial Carcinoma with FGFR Abnormalities
    Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Mutation
    Other Solid Tumors with FGFR Genetic Aberrations
    Major players covered
    Janssen Pharmaceuticals
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Erdafitinib Tablets product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Erdafitinib Tablets, with price, sales quantity, revenue, and global market share of Erdafitinib Tablets from 2021 to 2026.
    Chapter 3, the Erdafitinib Tablets competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Erdafitinib Tablets breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Erdafitinib Tablets market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Erdafitinib Tablets.
    Chapter 14 and 15, to describe Erdafitinib Tablets sales channel, distributors, customers, research findings and conclusion.

    Buy now